The drugs typically used to treat SSc-ILD are non-specific immunosuppressants (cyclophosphamide, mycophenolate), more specific immunosuppressive drugs including anti-IL-6 agents (tocilizumab) and anti-B-cell drugs (rituximab), and antifibrotics agents (nintedanib—a tyrosine kinase inhibitor) [6,88,89,95,96,97,98,101,102,103,104,105,106,107,108]. This evidence concerns the gene IL6 and interstitial lung disease.